Title

The Breast Cancer Research Scandal: Addressing the Issues

Document Type

Article

Publication Date

4-15-1995

Journal

Canadian Medical Association Journal

Volume

152

Issue

8

First Page

1195

Last Page

1197

Abstract

The three claims put forward by Dr. Roger Poisson to rationalize his enrollment of ineligible subjects in clinical trials do not justify research fraud. None the less, certain lessons for the conduct of clinical research can be learned from the affair: experimental therapies should be made available to technically ineligible subjects when no effective therapy exists for their disease; further research must investigate the possible benefits of clinical-trial participation; broadly based, pragmatic trials must be regarded as the ideal model; and each eligibility criterion in a clinical-trial protocol should be justified.

Notes

Dr. Charles Weijer is currently a faculty member of The University of Western Ontario.